A pretty dismal 4c imho.
""the Company has been evaluating several additional assets that could diversify risk for shareholders""
Well theres their next pump and rebranding if they cant get DX-1/3 BACK TO WORK..
Also ""The Company is reviewing its license obligations to, and agreements with, Yale University across the deoxymab technology platform ""
If they cant find a partner they wont be continuing paying Yale.....
Grim as fuxk
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.001(50.0%) |
Mkt cap ! $3.086M | |||
| Open | High | Low | Value | Volume |
| 0.1¢ | 0.2¢ | 0.1¢ | $505 | 380.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 42455979 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 36217092 | 16 |
View Market Depth
| Last trade - 14.39pm 16/06/2025 (20 minute delay) ? |
| PAB (ASX) Chart |